荣昌生物（09995.HK）今日盘中大涨5.06%，引起市场广泛关注。该公司于8月24日发布的2025年中期业绩报告显示，公司财务状况有所改善，推动股价强劲上涨。
根据公司公告，荣昌生物2025年上半年产品销售及研发服务收益达10.92亿元，同比增长47.6%。尽管公司仍处于亏损状态，但净亏损同比大幅减少42.4%，降至约4.5亿元。研发开支同比减少19.7%至6.47亿元，显示公司在控制成本方面取得进展。每股亏损为0.83元。
收益增长主要得益于公司自身免疫类商业化产品泰它西普及抗肿瘤类商业化产品维迪西妥单抗的销售放量。这表明公司的核心产品正逐步获得市场认可，为未来业绩增长奠定基础。此外，公司股东数量较今年3月底增加91.03%，达到1.29万户，反映出投资者对公司前景的信心增强。分析人士认为，荣昌生物在研发投入和商业化进程中取得的进展，以及财务状况的改善，是推动股价上涨的主要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.